| Literature DB >> 29812984 |
Shalini Jain1, Anna Panyutin1, Naili Liu1, Cuiying Xiao2, Ramón A Piñol2, Priyanka Pundir3, Clémence Girardet4, Andrew A Butler4, Xinzhong Dong3, Oksana Gavrilova1, Marc L Reitman2.
Abstract
Intraperitoneal administration of the melanocortin agonist melanotan II (MTII) to mice causes a profound, transient hypometabolism/hypothermia. It is preserved in mice lacking any one of melanocortin receptors 1, 3, 4, or 5, suggesting a mechanism independent of the canonical melanocortin receptors. Here we show that MTII-induced hypothermia was abolished in KitW-sh/W-sh mice, which lack mast cells, demonstrating that mast cells are required. MRGPRB2 is a receptor that detects many cationic molecules and activates mast cells in an antigen-independent manner. In vitro, MTII stimulated mast cells by both MRGPRB2-dependent and -independent mechanisms, and MTII-induced hypothermia was intact in MRGPRB2-null mice. Confirming that MTII activated mast cells, MTII treatment increased plasma histamine levels in both wild-type and MRGPRB2-null, but not in KitW-sh/W-sh, mice. The released histamine produced hypothermia via histamine H1 receptors because either a selective antagonist, pyrilamine, or ablation of H1 receptors greatly diminished the hypothermia. Other drugs, including compound 48/80, a commonly used mast cell activator, also produced hypothermia by both mast cell-dependent and -independent mechanisms. These results suggest that mast cell activation should be considered when investigating the mechanism of drug-induced hypothermia in mice.Entities:
Keywords: MRGPRB2; histamine; hypothermia; mast cell activation; melanocortin
Mesh:
Substances:
Year: 2018 PMID: 29812984 PMCID: PMC6171009 DOI: 10.1152/ajpendo.00024.2018
Source DB: PubMed Journal: Am J Physiol Endocrinol Metab ISSN: 0193-1849 Impact factor: 4.310